Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Merck
McKinsey
Dow

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ARICEPT ODT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Aricept Odt

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed Alzheimer's Disease Cooperative Study (ADCS) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed National Institute on Aging (NIA) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗ Study of the Pathogenesis of Rett Syndrome Completed Johns Hopkins University N/A 1995-01-01 OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 ↗ Study of the Pathogenesis of Rett Syndrome Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 1995-01-01 OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00018278 ↗ Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed US Department of Veterans Affairs Phase 4 1998-10-01 The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
NCT00018278 ↗ Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed VA Office of Research and Development Phase 4 1998-10-01 The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
NCT00024531 ↗ Lipitor as a Treatment for Alzheimer's Disease Completed Pfizer Phase 2 2000-10-01 The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aricept Odt

Condition Name

Condition Name for Aricept Odt
Intervention Trials
Alzheimer's Disease 36
Alzheimer Disease 21
Healthy 14
Dementia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aricept Odt
Intervention Trials
Alzheimer Disease 65
Dementia 25
Cognitive Dysfunction 19
Cognition Disorders 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aricept Odt

Trials by Country

Trials by Country for Aricept Odt
Location Trials
United States 340
Canada 46
Japan 28
Korea, Republic of 23
United Kingdom 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aricept Odt
Location Trials
California 25
Florida 21
Texas 21
New York 18
Arizona 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aricept Odt

Clinical Trial Phase

Clinical Trial Phase for Aricept Odt
Clinical Trial Phase Trials
Phase 4 32
Phase 3 21
Phase 2 36
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aricept Odt
Clinical Trial Phase Trials
Completed 111
Terminated 16
Unknown status 7
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aricept Odt

Sponsor Name

Sponsor Name for Aricept Odt
Sponsor Trials
Pfizer 18
Eisai Inc. 15
National Institute of Mental Health (NIMH) 9
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aricept Odt
Sponsor Trials
Industry 116
Other 90
NIH 25
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Johnson and Johnson
Harvard Business School
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.